Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global’s SEC disclosures dive deep into calcification studies, trial endpoints, and FDA milestones for its DurAVR THV system—details that can overwhelm even seasoned med-tech analysts. Finding when executives buy shares or how R&D spending shifts between valve iterations inside a 300-page filing is an added challenge.
Stock Titan solves that by pairing every submission with AI-powered summaries and plain-English tags. Whether you need the "Anteris Technologies insider trading Form 4 transactions" or the most recent "Anteris Technologies quarterly earnings report 10-Q filing", the platform pulls them the moment they hit EDGAR and explains what each metric means for market size, reimbursement pathways, and capital needs. You’ll see "Anteris Technologies Form 4 insider transactions real-time", "Anteris Technologies SEC filings explained simply", and "Anteris Technologies earnings report filing analysis" side-by-side with source PDFs, saving hours of manual scrolling.
Looking for deeper context? Our tools highlight how trial data in an 8-K could influence future approvals, compare pipeline costs across periods, and flag changes in covenant language that impact liquidity. It’s "understanding Anteris Technologies SEC documents with AI"—from the "Anteris Technologies executive stock transactions Form 4" to the "Anteris Technologies annual report 10-K simplified", the "Anteris Technologies proxy statement executive compensation" and even "Anteris Technologies 8-K material events explained". Track insider sentiment before a pivotal catalyst, gauge quarterly burn rate, or review governance terms in seconds. All filings, all in one place, translated into actionable insights so you can focus on investment decisions, not document hunting.
Anteris Technologies Global Corp. (AVR) reported continued development-stage results as it scales toward a pivotal US trial. Net sales were $0.6 million for Q2 2025 and $1.17 million for the six months, while operating investment drove a loss after tax of $42.99 million for the six months ended June 30, 2025. Cash declined to $28.4 million from $70.5 million at year-end 2024 as operating cash outflows totaled $41.0 million in H1 2025.
The company increased R&D spending to $32.8 million for H1 2025 to scale manufacturing and prepare the PARADIGM randomized pivotal trial; 79 sites are qualified for that study. Anteris completed a U.S. IPO and received net proceeds of $80.0 million (including the over-allotment), but management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital.
Anteris Technologies Global Corp. (Nasdaq AVR) has filed a PRE 14A calling a fully virtual special meeting for 4 Sep 2025.
Shareholders will vote on: (1) ASX’s three-year waiver of Listing Rule 7.1, allowing equity issuances above the current 15 % cap without prior ASX shareholder approval, and (2) authority to adjourn the meeting to gather more proxies if Proposal 1 lacks support.
The board argues the waiver aligns AVR with U.S. peers and provides funding flexibility for the DurAVR THV program, while Nasdaq’s 20 % and change-of-control rules will still govern large deals.
Proposal 1 needs 75 % of votes cast; Proposal 2 needs a simple majority. Illustrative scenarios show potential shareholder dilution from 8 % up to 73 %, depending on deal size and price. Record date is 11 Aug 2025; CDI holders must instruct CDN to vote on their behalf.
The board unanimously recommends voting FOR both proposals.
FAQ
What is the current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
What is the market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
